Company Encyclopedia
View More
name
CanSinoBIO
688185.SH
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides.
1.579 T
688185.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking27/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-2.84%D
    • Profit Margin-14.62%D
    • Gross Margin82.15%A
  • Growth ScoreB
    • Revenue YoY29.83%A
    • Net Profit YoY80.28%A
    • Total Assets YoY-8.62%E
    • Net Assets YoY-2.61%D
  • Cash ScoreC
    • Cash Flow Margin-684.22%E
    • OCF YoY29.83%A
  • Operating ScoreE
    • Turnover0.13E
  • Debt ScoreB
    • Gearing Ratio32.46%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cansino Biologics Inc. Appoints Man Cho and Xuefeng Ji as Independent Non-Executive Director and Adjusts Composition of the Committees

    CanSino Biologics Inc. appointed Man Cho and Xuefeng Ji as independent non-executive directors and adjusted its committee compositions at the EGM on November 27, 2025. Changes include new chairpersons and members for the Audit, Remuneration and Assessment, and Nomination Committees, effective until the end of the third session of the Board of Directors.

    marketscreener·
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%
    marketscreener·
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%

    Morning Trend | Tonix Pharmaceuticals Holding experiences significant intraday volatility, is a rebound trend about to start?

    Tonix Pharmaceuticals Holdings (TNXP.US) showed a significant surge in trading volume yesterday, with the previously stagnant small-cap pharmaceutical stocks experiencing a return of institutional investors, and community FOMO sentiment gradually rising. The stock price broke through short-term moving average resistance, igniting trading enthusiasm in the morning session, as bulls attempted to dominate the market. Although there are currently no major favorable policies in the pharmaceutical industry, speculation surrounding vaccine development and industry policy adjustments has resurfaced, transmitting to the small-cap biotech sector, where capital competition is rapidly heating up. Institutions quickly built positions and lifted prices in the low volatility zone, raising short-term attention. Technically, the daily K-line formed a large bullish candle, breaking through the upper band of the moving average system, with the MACD indicator also turning upward. The main funds made three upward pushes in intraday trading, with sufficient follow-up capital, indicating strong momentum. Today, attention should be paid to whether the gentle increase in volume can be sustained. If the short-term enthusiasm for chasing prices continues, it may ignite a rally in small-cap pharmaceutical stocks. Caution is needed against potential follow-up buying failing to sustain, which could lead to a quick cooling of the market as institutions take profits. For right-side traders, Tonix's intraday volatility today is an important signal for the initiation of a rebound trend

    Technical Forecast·
    SZ
    300142
    +0.34%
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%
    Technical Forecast·
    SZ
    300142
    +0.34%
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%

    Sinovac: Signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, creating the largest international order for Chinese vaccines

    Sinovac has signed a ten-year vaccine cooperation agreement with the Brazilian Ministry of Health, becoming the first Chinese vaccine company to win the bid for this project. Sinovac will collaborate with Brazil's Tecpar Institute and Eurofarma to provide approximately 60 million doses of varicella and rabies vaccines to Brazil over the next ten years, with a contract amount exceeding 700 million USD, setting a record for the largest international order for a Chinese vaccine company

    Wallstreetcn·
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%
    SH
    603392
    +0.37%
    Wallstreetcn·
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%
    SH
    603392
    +0.37%

    UBS lists predictions for Chinese stocks with high profit growth potential for next year (Table)

    UBS released a strategy report on the Chinese market, listing Chinese stocks with high profit growth potential for next year and giving them a "Buy" rating. The list includes Hong Kong stocks and Chinese concept stocks, such as InnoCare Pharma, Kintor Pharmaceutical, Zai Lab, Akeso, ECARX Holdings, CanSinoBIO, Zhongsheng Holdings, BeiGene, Li Auto, GDS Holdings, and iQIYI

    AASTOCKS·
    US
    ZLAB
    +1.01%
    HK
    09688
    -0.51%
    SH
    688185
    +0.64%
    AASTOCKS·
    US
    ZLAB
    +1.01%
    HK
    09688
    -0.51%
    SH
    688185
    +0.64%

    CanSino Biologics Launches Phase I Trial for Inhaled TB Booster in Indonesia

    CanSino Biologics Inc. has launched a Phase I clinical trial for its inhaled tuberculosis vaccine in Indonesia, enrolling the first patient. The trial will assess the safety and immunogenicity of a single dose of the inhaled TB Booster in adults aged 18 to 49. The vaccine aims to stimulate an immune response in the lungs to combat tuberculosis. Results are pending.

    Reuters·
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%
    Reuters·
    SH
    688185
    +0.64%
    HK
    06185
    -1.09%
    © 2025 Longbridge｜Disclaimer